-
Mashup Score: 0Testing a new measure of lupus improvement that encompasses the patients’ perspectives and doctors’ evaluations | Lupus Science and Medicine Podcast - 6 month(s) ago
Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Anca Askanase and Joan Merrill, the developers of the LFA-REAL tool. Together, they discuss the importance of using a tool like LFA-REAL to understand how clinician and patient reported outcomes are essential for understanding efficacy and effectiveness of experimental therapeutics developed to treat people living with lupus. Read the article: http://dx.doi.org/10.1136/lupus-2022-000875
Source: lupusbmj.podbean.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1article - 7 month(s) ago
IntroductionChronic lymphocytic leukemia (CLL) is the most common type of leukemia affecting adults in western countries, mainly affecting older adults, with a median age at diagnosis of 72 years;1,2 its incidence and prevalence are expected to further increase in the short-term, proportionally increasing with the aging of the population.Chemo-immunotherapy regimens (eg, fludarabine…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Chemo-immunotherapy regimens have been the standard of care for #ChronicLymphocyticLeukemia. Yet, novel targeted agents—like #BTK and B-cell lymphoma-2 inhibitors—offer therapeutic options with higher #efficacy and personalized treatment. Learn more: https://t.co/BOKL4lNyrg #CLL https://t.co/2eC26XEqnd
-
-
Mashup Score: 0PV: Novel rusfertide shows ‘impressive’ efficacy - 9 month(s) ago
The novel synthetic form of liver hormone hepcidin represents a “paradigm shift” in polycythemia vera treatment, allowing patients to avoid the need for phlebotomy.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial - 10 month(s) ago
AbstractAims. Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure with mildly reduced o
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0
Sparing lymph nodes until after immunotherapy treatment may result in improved antitumor immune response among patients with cancer, according to a study published in Cell. “This study helps clarify how immunotherapies work and where the reservoir of cells is that is responding to the therapies, so we can think about developing better immunotherapies that harness those cells in the lymph
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma - 1 year(s) ago
The Global Initiative for Asthma (GINA) guidelines recommend stepwise changes in treatment intensity, including inhaled corticosteroid (ICS) dose, to achieve disease control in patients with asthma.1 The GINA treatment for moderate asthma includes maintenance therapy of medium-dose ICS plus a long-acting β2 agonist (LABA) or other controller(s), while treatment for severe asthma includes…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0
A novel, once-daily, fixed-dose combination of mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY) delivered via Breezhaler® is the first inhaled corticosteroid/long-acting ꞵ2-agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy approved for the maintenance treatment of asthma in adults inadequately controlled on ICS/LABA combination. In patients with asthma…
Source: Respiratory MedicineCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0
A growing number of studies have shown encouraging results with omalizumab (OMA) as monotherapy and as an adjunct to oral immunotherapy (OMA+OIT) in patients with single/multiple food allergies.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 2B Cell Reconstitution is Associated With COVID-19 Booster Vaccine Responsiveness in Patients Previously Seronegative Treated With Rituximab - 1 year(s) ago
Objective To assess factors associated with serologic response to the coronavirus 2019 (COVID-19) booster vaccine in patients with autoimmune rheumatic diseases treated with rituximab (RTX) who were previously serologically unresponsive to the initial vaccine series. Methods A retrospective chart review of patients treated with RTX who failed to demonstrate a serologic response to the first…
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Importance of SARS-CoV-2 Spike Antibodies and B Cell Reconstitution to Optimize the Prevention Strategy of COVID-19 - 1 year(s) ago
Several lines of evidence have shown that rituximab (RTX)-treated patients are at high risk of severe coronavirus disease 2019 (COVID-19).1 Thus, health authorities have considered patients receiving RTX as extremely high priority for anti-SARS-CoV-2 vaccination. However, a major issue relates to the high risk of reduced vaccination efficacy in these patients.2 Indeed, a metaanalysis conducted in…
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet
New #podcast- importance of using a #tool like #LFA-REAL to understand how #clinician & #patient reported #outcomes r essential for understanding #efficacy & #effectiveness of #experimental #therapeutics developed to treat people living w/ #lupus #SLE https://t.co/UXgCwZL5Ix